Halozyme Therapeutics (HALO) Cash & Equivalents (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Cash & Equivalents data on file, last reported at $309.7 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 75.67% year-over-year to $309.7 million in Q1 2026; TTM through Mar 2026 was $309.7 million, a 75.67% increase from a year earlier, with the FY2025 full-year figure at $133.8 million, up 15.51% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $309.7 million, up from $133.8 million in the prior quarter.
• Over the last five years, Cash & Equivalents for HALO reached as high as $419.7 million in Q3 2025 and fell as low as $61.9 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $177.9 million across 5 years, with a median of $154.3 million in 2024.
• Across the five-year window, Cash & Equivalents tumbled 79.66% in 2022 and jumped 171.95% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $234.2 million in 2022, then slumped by 49.46% to $118.4 million in 2023, then fell by 2.13% to $115.8 million in 2024, then advanced by 15.51% to $133.8 million in 2025, then jumped by 131.47% to $309.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $309.7 million in Q1 2026, $133.8 million in Q4 2025, and $419.7 million in Q3 2025.